文献速递冠心病

慢性冠心病患者在不同肾功能分期下侵入性与保守治疗的临床及生活质量结局

Clinical and Quality-of-Life Outcomes Following Invasive vs Conservative Treatment of Patients With Chronic Coronary Disease Across the Spectrum of Kidney Function.
PubMed 文献 · JAMA Cardiol · 2022-01-01

本研究基于ISCHEMIA和ISCHEMIA-CKD试验,按CKD分期分析5956例慢性冠心病患者。结果显示,随着CKD分期升高,主要复合终点(死亡或非致死性心梗)风险单调增加;侵入性治疗增加卒中及围术期心梗风险、降低自发性心梗风险,各CKD分期效应相似,但生活质量改善仅见于CKD 1-3期。

要点

  • CKD分期越高,死亡或非致死性心梗复合终点风险越高。
  • 侵入性治疗增加卒中和围术期心梗,但降低自发性心梗,各期效应一致。
  • 侵入性治疗改善心绞痛相关生活质量仅见于CKD 1-3期,CKD 4-5期无此获益。

核心结论

  • 在慢性冠心病患者中,事件发生率与肾功能呈负相关。
  • 侵入性治疗增加卒中和围术期心梗风险、降低自发性心梗风险,各CKD分期效应相似,包括死亡在内的其他结局无差异。
  • 侵入性治疗对生活质量的改善在肾功能较差者中未观察到。

研究设计与样本

  • 研究纳入ISCHEMIA和ISCHEMIA-CKD试验的5956例参与者,按CKD分期1至5期分类。
  • 纳入时间为2012年7月26日至2018年1月31日,中位随访3.1年。
  • 干预为初始侵入性管理(冠状动脉造影和血运重建联合指南导向药物治疗)对比初始保守管理(仅指南导向药物治疗)。

主要发现

  • CKD 1至5期3年主要复合终点发生率分别为9.52%、10.72%、18.42%、34.21%和38.01%。
  • 侵入性管理3年卒中事件率差异为1%(95%CI 0.3至1.7),围术期心梗差异为1.6%(95%CI 0.9至2.3),自发性心梗差异为-2.5%(95%CI -3.9至-1.1)。
  • 生活质量结局存在治疗效应异质性:侵入性管理改善CKD 1-3期患者心绞痛相关生活质量,CKD 4-5期无改善。

关键数值与推荐

  • CKD分期定义:1期eGFR≥90 mL/min/1.73m2,2期60-89,3期30-59,4期15-29,5期<15或透析。
  • 主要临床结局为死亡或非致死性心肌梗死复合终点,主要生活质量结局为西雅图心绞痛问卷总结评分。

临床怎么用

  • 临床决策应结合肾功能分期评估侵入性治疗的获益与风险。
  • 对CKD 1-3期患者,侵入性治疗可能改善心绞痛相关生活质量。
  • 对CKD 4-5期患者,侵入性治疗未显示生活质量获益,需个体化权衡。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Prior trials of invasive vs conservative management of chronic coronary disease (CCD) have not enrolled patients with severe chronic kidney disease (CKD). As such, outcomes across kidney function are not well characterized. OBJECTIVES: To evaluate clinical and quality-of-life (QoL) outcomes across the spectrum of CKD following conservative and invasive treatment strategies. DESIGN, SETTING, AND PARTICIPANTS: Participants from the International Study of Comparative Health Effectiveness With Medical and Invasive Approaches (ISCHEMIA) and ISCHEMIA-Chronic Kidney Disease (CKD) trials were categorized by CKD stage: stage 1 (estimated glomerular filtration rate [eGFR] 90 mL/min/1.73m2 or greater), stage 2 (eGFR 60-89 mL/min/1.73m2), stage 3 (eGFR 30-59 mL/min/1.73m2), stage 4 (eGFR 15-29 mL/min/1.73m2), or stage 5 (eGFR less than 15 mL/min/1.73m2 or receiving dialysis). Enrollment took place from July 26, 2012, through January 31, 2018, with a median follow-up of 3.1 years. Data were analyzed from January 2020 to May 2021. INTERVENTIONS: Initial invasive management of coronary angiography and revascularization with guideline-directed medical therapy (GDMT) vs initial conservative management of GDMT alone. MAIN OUTCOMES AND MEASURES: The primary clinical outcome was a composite of death or nonfatal myocardial infarction (MI). The primary QoL outcome was the Seattle Angina Questionnaire (SAQ) summary score. RESULTS: Among the 5956 participants included in this analysis (mean [SD] age, 64 [10] years; 1410 [24%] female and 4546 [76%] male), 1889 (32%), 2551 (43%), 738 (12%), 311 (5%), and 467 (8%) were in CKD stages 1, 2, 3, 4, and 5, respectively. By self-report, 18 participants (<1%) were American Indian or Alaska Native; 1676 (29%), Asian; 267 (5%), Black; 861 (16%), Hispanic or Latino; 18 (<1%), Native Hawaiian or Other Pacific Islander; 3884 (66%), White; and 13 (<1%), multiple races or ethnicities. There was a monotonic increase in risk of the primary composite end point (3-year rates, 9.52%, 10.72%, 18.42%, 34.21%, and 38.01% respectively), death, cardiovascular death, MI, and stroke in individuals with higher CKD stages. Invasive management was associated with an increase in stroke (3-year event rate difference, 1%; 95% CI, 0.3 to 1.7) and procedural MI (1.6%; 95% CI, 0.9 to 2.3) and a decrease in spontaneous MI (-2.5%; 95% CI, -3.9 to -1.1) with no difference in other outcomes; the effect was similar across CKD stages. There was heterogeneity of treatment effect for QoL outcomes such that invasive management was associated with an improvement in angina-related QoL in individuals with CKD stages 1 to 3 and not in those with CKD stages 4 to 5. CONCLUSIONS AND RELEVANCE: Among participants with CCD, event rates were inversely proportional to kidney function. Invasive management was associated with an increase in stroke and procedural MI and a reduced risk in spontaneous MI, and the effect was similar across CKD stages with no difference in other outcomes, including death. The benefit for QoL with invasive management was not observed in individuals with poorer kidney function.

来源:JAMA Cardiol,查看原文。版权归原作者所有。

引用

  1. Bangalore S, Hochman JS, Stevens SR, et al. Clinical and Quality-of-Life Outcomes Following Invasive vs Conservative Treatment of Patients With Chronic Coronary Disease Across the Spectrum of Kidney Function. JAMA Cardiol. 2022. PMID: 35767253. doi:10.1001/jamacardio.2022.1763

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。